未找到相关数据
Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.
被引：6
作者：
Liu, Joyce F.
Barry, William Thomas
Birrer, Michael J.
Lee, Jung-min
Buckanovich, Ronald J.
Fleming, Gini F.
Rimel, B. J.
Buss, Mary K.
Nattam, Sreenivasa R.
Hurteau, Jean
Luo, Weixiu
Farooq, Sarah
Whalen, Christin
Kohn, Elise C.
Ivy, S. Percy
Matulonis, Ursula A.
机构：
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.5535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5535
引用
收藏
页数：4
相关论文